Aclaris Therapeutics Completes Enrollment In Phase 2B Study Of Oral Zunsemetinib (ATI-450) For Moderate To Severe Rheumatoid Arthritis; Topline Data Anticipated In Q4 2023
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics has completed enrollment in its Phase 2B study of oral Zunsemetinib (ATI-450) for moderate to severe rheumatoid arthritis. Topline data is expected in Q4 2023.
June 13, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics' completion of enrollment in the Phase 2B study of Zunsemetinib (ATI-450) may positively impact its stock price in the short term.
The completion of enrollment in the Phase 2B study of Zunsemetinib (ATI-450) indicates progress in Aclaris Therapeutics' drug development pipeline. This news may be seen as a positive milestone by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100